Amaero Got Its Nasdaq Listing. Now It Has to Absorb Its Own Factory
A $13.4M firm backlog, 35% growth and a formal Q4 guide — delivered alongside a $4.4M gross loss as titanium capacity sat under-utilized
3DA.AX · Earnings Call · 2026-11-09
The listing did more work than any single line item
Amaero's inaugural Nasdaq call is also its first reported in US dollars under US GAAP, and the reframing deserves more attention than it got. In April, management “reaffirmed $18 million to $20 million guidance” — Hank Holland, Chairman and CEO · 2026-04-21 for the fiscal year ending June. That number appears nowhere in today's materials. Instead we get a calendar-2026 framework: $16.0–16.5 million, up 154%–162%, with Q4 guided to $4.5–5.0 million. The bridge is real — the June year actually produced $12.5 million, which is roughly the old Australian-dollar range translated — but the currency and fiscal-year conversion quietly retired a guidance framework that had been reaffirmed twice. No analyst asked about it. What the new wrapper does deliver is a firmer contract: a formal Q4 range, a cost structure management calls largely sunk, and a backlog of $13.44 million — backlog up 180% year-over-year and roughly equal to trailing-twelve-month revenue of $13.5 million. Thematically, the chairman's framing is unchanged from prior calls: rebuilding the US defense industrial base, reshoring, and additive manufacturing, with Department of War money and a first low-rate production contract now attached to it. That theme is not company-unique anymore — defense-industrial reporters across this window (Kratos, Loar, Ducommun, Mercury, Rheinmetall) are all narrating the same funding cycle.The quarter that growth built and cost accounting ate
Revenue rose 35% to $4.11 million, near the top of the pre-announced range. Metal powders contributed $3.2 million (+19%); PM HIP contributed $0.9 million, up 146%, including the first revenue from the BPMI contract. Then the other line: cost of revenue of $8.5 million against $4.11 million of sales, producing a $4.4 million gross loss, a net loss of $9.06 million ($0.38 per share), and adjusted EBITDA of negative $7.1 million. Management's explanation is specific and, notably, self-inflicted by success of a sort. Titanium production restarted in late July after the six-week safety pause — a dust-hazard review with Jensen Hughes that has since vanished from the conversation entirely — and then the new sieving system was commissioned in August. Hank Holland was blunt: “the sieving is the bottleneck process of powder production” — Hank Holland, Chairman and Chief Executive Officer · 2026-11-09, and “the yield was below optimal for last quarter” — Hank Holland, Chairman and Chief Executive Officer · 2026-11-09. Unabsorbed production labor plus poor yields turned a growth quarter into a negative gross margin. The bull argument is that this is a fixed-cost story. Brett Paduch: “the fixed cost in our cost of goods sold is significantly scaled at this point” — Brett Paduch, Chief Financial Officer · 2026-11-09. Fair — but Holland immediately dampened it, flagging a six-week inventory lag and conceding “we really will not begin to see the favorable trend as we would expect until we get into the next calendar year” — Hank Holland, Chairman and Chief Executive Officer · 2026-11-09. So Q4 gets the revenue, not the margin. Here is the tension that matters most. Six months ago the titanium story was scarcity:Today, titanium ran below installed capacity. And the company still intends to commission its fourth atomizer in June 2027, lifting capacity from roughly 680 metric tons to 920 — adding supply into a line that just demonstrated it cannot yet fill what it has. That is the pivot from build-out to execution, and it is less comfortable than the press release implies.This current quarter, on the atomizer dedicated titanium, we are adding 100% capacity utilization. We're full. We cannot accept other orders this quarter.